CEACAM5 and non-small cell lung carcinoma: Importantly, no patients had a grade 4 (perforation or BCVA worse than 20/200 in the affected eye) event, and no patients discontinued treatment due to ocular AEs.54 ORRs with tusamitamab ravtansine 100 mg/m2 were 33.3% in the dose-escalation phase in patients with advanced solid tumors and 20.3% in the dose-expansion phase (patients with NSCLC and high CEACAM5 expression) (Table 3).51,52 CEACAM5 has not been detected on corneal tissue; thus, ocular AEs reported with tusamitamab ravtansine are likely due to off-target toxicity.